

Contact:**Punnie Donohue**

ConvaTec

punnie.donohue@convatec.com

ConvaTec Enters \$1.7B Negative Pressure Wound Therapy Market with Launch of Avelle™ System

- *First system to combine Negative Pressure with the benefits of AQUACEL® Technology*
- *Lightweight, disposable system offers extended wear, up to 30 days, suitable across different care settings*

LUXEMBOURG (4 August 2016) — ConvaTec, a leading global medical technology company, today announced the UK launch of the Avelle™ Negative Pressure Wound Therapy (NPWT) System, the company's entry into the \$1.7 billion negative pressure market.

The innovative Avelle™ System is the first to combine negative pressure wound therapy with the benefits of AQUACEL® Technology.

The Avelle™ System delivers negative pressure wound therapy in a simple, canister-less system, allowing flexibility across different care settings. The small, ergonomically-shaped pump fits within a pocket and runs quietly for added discretion. The disposable pump also has a 30 day lifetime* giving the option of extended wear and therapy, and an economic advantage over pumps with shorter lifetimes.

The Avelle™ System incorporates the Avelle™ dressing that is powered by AQUACEL® Technology which helps prevent periwound maceration,**¹ a potential complication associated with NPWT that can lead to delayed healing.² AQUACEL® is ConvaTec's proprietary technology that is designed to help create a beneficial moist wound environment for healing.³

The Avelle™ System's lightweight, portable and easy-to-use design enables patients to have enhanced mobility, helping them resume their daily activities, both in and out of the home, as their wounds heal.

"Specialists have long depended on AQUACEL® and the unique fluid-handling capabilities of Hydrofiber® Technology to progress healing for a variety of patients' wounds," said Joy Tickle, Tissue Viability Specialist, MSc, BSc(hons), Cert Ed, RGN, NDN. "Now, we can have the benefits of this leading technology in combination with negative pressure wound therapy – and bring even more benefits to our patients."

"The launch of Avelle™ NPWT provides a unique proposition to wound care specialists by bringing together the benefits of negative pressure and proven AQUACEL® Technology in an easy to use, disposable system suitable for use from hospital to home on many different types of wounds," said Fiona Adam, Vice President and General Manager of Advanced Wound Care. "ConvaTec's entry to

the negative pressure market demonstrates our dedication and commitment to the community of wound care specialists and patients whom we serve and whose lives we touch, every day.”

The Avelle™ System can be used on a broad range of low to moderately-exuding wound types, including chronic, acute, traumatic, sub-acute and dehisced wounds, skin grafts, and surgically closed incisions. The Avelle™ NPWT System received CE mark approval and commercial launch process commenced in the UK with clinical evaluations with key customers. This program will be extended to additional markets to drive early adoption across Europe.

For more information, visit <http://www.convatec.co.uk/wound-skin/avelle-negative-pressure-wound-therapy-system/#> or call ConvaTec customer service at 0800 289 738.

###

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. The company is owned by Nordic Capital and Avista Capital Partners.

*Battery change may be required during pump lifetime.

**As demonstrated in vitro

Avelle, AQUACEL and Hydrofiber are trademarks of ConvaTec Inc.

© 2016 ConvaTec Inc.

AP-016734-MM EM

¹ Waring MJ, Parsons D, Physico-chemical characterisation of carboxymethylated spun cellulose fibres. *Biomaterials*. 2001;22(9):903-912.

² Hanft JR, Henao M. How To Prevent Periwound Maceration With VAC Therapy. *Podiatry Today*. 2010; 23(6)

³ Bishop SM, Walker M, Rogers AA, Chen WYJ. Moisture balance: optimizing the wound-dressing interface. *J Wound Care*. 2003;12:125-128.